Comments

Roivant Sciences

Q: What sector and industry does Roivant Sciences (ROIV) operate in?

Roivant Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ROIVNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$11.20

-0.44-3.78%

At close: -

$11.12

-0.08-0.71%

After Hours: 7:44 PM EDT

Q2 2025 Earnings were released on Tue Nov 12th, before the market open

The most recent conference call was at 8:00 AM, 4 days ago Click to view past webcast

Roivant Sciences (ROIV) Forecast

News Earnings Roivant Sciences (ROIV) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Overview Rating

Good

Technicals Analysis

100

0100

Financials Analysis

0100

Roivant Sciences (NASDAQ:ROIV) Stock Quotes, Forecast and News Summary

Roivant Sciences Stock (NASDAQ: ROIV) stock price, news, charts, stock research, profile.

Open	$11.56
Close	$11.20
Volume / Avg.	8.38M / 5.89M
Day Range	$11.14 - $11.61
52 Wk Range	8.56 - 13.06
Market Cap	$8.22B
P/E Ratio	2.03
Dividend Yield	-
Exchange	NASDAQ
RSI	39
Short Interest	8.53%
Days to Cover	14.26

Recent News

Organon, Howmet Aerospace And More: CNBC's 'Final Trades'

On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners named ProShares Short QQQ as his final trade.

Avi Kapoor

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including FDA-approved Vtama cream for plaque psoriasis. The deal, valued up to $1.2 billion.

Vandana Singh

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $14 million and up to $280 million in future milestone payments.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jul

Aug

Sep

Nov

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$11.56
Close	$11.20
Volume / Avg.	8.38M / 5.89M
Day Range	$11.14 - $11.61
52 Wk Range	8.56 - 13.06
Market Cap	$8.22B
P/E Ratio	2.03
Dividend Yield	-
Exchange	NASDAQ
RSI	39
Short Interest	8.53%
Days to Cover	14.26

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Roivant Sciences (ROIV) stock?

You can purchase shares of Roivant Sciences (NASDAQ:ROIV) through any online brokerage.

View our list of the best stock brokerages

Who are Roivant Sciences (ROIV) competitors?

Other companies in Roivant Sciences’s space includes: Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR).

What is the forecast, or price target, for Roivant Sciences (ROIV) stock?

Roivant Sciences has a consensus price target of $16.41.

What is the current price for Roivant Sciences (ROIV)?

The stock price for Roivant Sciences (NASDAQ: ROIV) is $11.12 last updated November 15, 2024 at 7:44 PM EST.

Does Roivant Sciences (ROIV) pay a dividend?

There are no upcoming dividends for Roivant Sciences.

When is Roivant Sciences (NASDAQ:ROIV) reporting earnings?

Roivant Sciences’s Q3 earnings are confirmed for Tuesday, February 11, 2025.

Is Roivant Sciences (ROIV) going to split?

There is no upcoming split for Roivant Sciences.

What sector and industry does Roivant Sciences (ROIV) operate in?

Roivant Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.